HALDOL SOLUTAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALDOL SOLUTAB (HALDOL SOLUTAB).
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
| Metabolism | Hepatic via CYP3A4, CYP2D6, and glucuronidation; major metabolite is reduced haloperidol. |
| Excretion | Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation. |
| Half-life | Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing. |
| Protein binding | Approximately 90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 14-17 L/kg; extensive tissue distribution with high lipophilicity. |
| Bioavailability | Oral: 60-70% (first-pass metabolism); intramuscular: 100%. |
| Onset of Action | Oral: 30-60 minutes for initial sedative effect; antipsychotic effect may require several days to weeks. |
| Duration of Action | Oral: 12-24 hours for single dose; steady-state achieved in 4-6 days; prolonged effects with depot formulations. |
| Molecular Weight | 375.86 |
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl >30 mL/min). For severe renal impairment (CrCl <30 mL/min), start at low end of dosing range and titrate cautiously; monitor for excessive sedation and hypotension. |
| Liver impairment | In Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): reduce dose by 50% and titrate slowly. Child-Pugh Class C (severe): avoid use or use with extreme caution at 25% of normal starting dose. |
| Pediatric use | For agitation or tic disorders: 0.05 to 0.15 mg/kg/day orally in 2 to 3 divided doses; maximum 6 mg/day (for children 3-12 years). Not recommended for children <3 years. For acute psychosis: 0.01 to 0.03 mg/kg intramuscularly every 4 to 8 hours as needed. |
| Geriatric use | Initiate at 0.5 to 2 mg orally once or twice daily; titrate slowly by 0.5 mg increments. Maximum dose typically 5 mg/day due to increased risk of QTc prolongation, extrapyramidal symptoms, and cognitive impairment. |
| 1st trimester | Limited human data; animal studies show risk. Use only if benefit outweighs risk. Possible risk of congenital malformations (e.g., limb defects) based on case reports. |
| 2nd trimester | Avoid unless necessary; may cause extrapyramidal symptoms in neonate if used near term. |
| 3rd trimester | Avoid in third trimester due to risk of neonatal withdrawal (abnormal muscle movements, agitation, feeding difficulties) and extrapyramidal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for HALDOL SOLUTAB (HALDOL SOLUTAB).
| Placental transfer | Haloperidol crosses the placenta; cord blood concentrations are similar to maternal serum levels. |
| Breastfeeding | Haloperidol is excreted into breast milk in low concentrations (relative infant dose ~2-12%). Monitor infant for sedation, irritability, or abnormal movements. Usually considered compatible with breastfeeding, but weigh risks vs benefits. |
■ FDA Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis.
| Serious Effects |
ComaSevere toxic central nervous system depressionParkinson's disease (unless specifically indicated)Known hypersensitivity to haloperidolProlonged QT interval (congenital or acquired)
| Precautions | Tardive dyskinesia, Neuroleptic malignant syndrome, QT prolongation, Central nervous system depression, Seizures, Dysphagia, Hepatotoxicity, Leukopenia/neutropenia |
| Food/Dietary | Avoid grapefruit and grapefruit juice; may increase haloperidol plasma concentrations and risk of adverse effects. Limit caffeine intake as it may exacerbate agitation or insomnia. Avoid alcohol due to additive CNS depression. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited data, but haloperidol crosses placenta. Risk of limb malformations and cardiac defects in first trimester exposure, though absolute risk low. Second and third trimesters: Neonatal extrapyramidal symptoms, withdrawal, and sedation reported with third trimester use. |
| Fetal Monitoring | Monitor maternal vital signs, EPS (extrapyramidal symptoms), QT interval (ECG if other risk factors). Fetal ultrasound for anomalies if first trimester exposure. Neonatal monitoring for EPS, respiratory depression, and withdrawal symptoms after delivery. |
| Fertility Effects | Haloperidol may elevate prolactin levels, leading to menstrual irregularities, galactorrhea, and impaired fertility in women. In men, possible decreased libido and erectile dysfunction. Effects reversible upon discontinuation. |
| Clinical Pearls | Haldol Solutab (haloperidol orodispersible tablet) is used for acute psychosis and agitation. It disintegrates rapidly on the tongue without water, useful for patients with swallowing difficulties or poor cooperation. Monitor for QT interval prolongation, especially in elderly or those on other QT-prolonging drugs. May cause extrapyramidal symptoms (EPS); consider prophylactic anticholinergic if history of EPS. Avoid in Parkinson's disease, Lewy body dementia, and patients with hypersensitivity. |
| Patient Advice | Place the tablet on your tongue; it will dissolve quickly without water. · Do not crush or chew the tablet; allow it to dissolve completely. · Avoid alcohol while taking this medication, as it can increase drowsiness and dizziness. · Get up slowly from sitting or lying down to prevent dizziness. · This medication may cause drowsiness; avoid driving or operating machinery until you know how it affects you. · Report any uncontrolled muscle movements, restlessness, or stiffness to your doctor immediately. · Avoid grapefruit and grapefruit juice, as they can increase haloperidol levels and side effects. · Take as prescribed; do not stop suddenly unless directed by your doctor, as withdrawal symptoms may occur. |